Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA new revision label 'v3.3.2' appears, replacing 'v3.2.0', indicating a site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedRemoved the generic government funding and operating status notice from the page; study details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedNo changes detected; the two screenshots show the same study details page.SummaryDifference0.4%

- Check70 days agoChange Detected- Added a government funding notice with operational details and links; - Updated version to v3.2.0; - Removed reference to v3.1.0.SummaryDifference3%

- Check77 days agoChange DetectedUpdate indicates a new software release (v3.1.0) replacing the previous v3.0.2—no other substantive content changes are shown.SummaryDifference0.1%

- Check92 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.